Kidney Cancer

Study Points to a Rise in Renal Carcinomas in Children

Publish Date August 3, 2020

The increase is thought to be related to environmental factors.

A Combination of Potential Biomarkers May Help Predict Response to Immunotherapy in mRCC

Publish Date July 31, 2020

Combining 2 predictors yielded better results than just using 1.

Sarcomatoid Features in mRCC Predict Worse Survival After Cytoreductive Nephrectomy

Publish Date July 21, 2020

Patients who have metastatic renal cell carcinoma with sarcomatoid differentiation in the primary tumor have an increased risk for death following cytoreductive nephrectomy, study found.

Cytoreductive Nephrectomy for mRCC Beneficial in Selected Cases

Publish Date July 18, 2020

Upfront cytoreductive nephrectomy for mRCC patients with certain clinical characteristics may enable them to defer systemic therapy for a prolonged interval.

Hemodialysis Ups Kidney Cancer Death Risk

Publish Date July 8, 2020

Among patients with renal cell carcinoma, those on hemodialysis have a 5 times higher risk of dying from the cancer than those not on dialysis, a study found.

Immunotherapy May Increase Risk for Hospitalization, Severe Respiratory Illness From COVID-19

Publish Date July 6, 2020

Patients with cancer and COVID-19 had high rates of hospitalization and/or respiratory illness, particularly among those taking immunotherapy or those older than 65 years.

Cytoreductive Nephrectomy in mRCC Does Not Improve Survival, Real-World Study Finds

Publish Date June 29, 2020

In a real-world study, cytoreductive nephrectomy (CN) prior to treatment with tyrosine kinase inhibitors did not improve survival for CN recipients overall, but did improve cancer-specific and progression-free survival in certain subgroups.

Antitumor Activity Reported With Lenvatinib/Pembrolizumab in Metastatic RCC After Disease Progression on ICI Therapy

Publish Date June 17, 2020

Lenvatinib plus pembrolizumab resulted in antitumor activity in patients with metastatic clear cell RCC that progressed during or after treatment with an immune checkpoint inhibitor, according to phase 2 results.

Response-Based Addition of Ipilimumab to Nivolumab Not Effective in RCC

Publish Date June 16, 2020

The response-based addition of ipilimumab to nivolumab in the treatment of advanced RCC resulted in few responses among patients who did not achieve a response with nivolumab alone, according to results of a phase 2 trial.

Nivolumab Plus Ipilimumab Demonstrated Promising Activity in Previously ICI-Treated RCC

Publish Date June 15, 2020

Preliminary phase 2 data suggest that nivolumab plus ipilimumab was efficacious in advanced RCC that previously progressed with immune checkpoint inhibitor therapy.